124 results
8-K
EX-99.1
PRTA
Prothena Corporation plc
8 May 24
Prothena Reports First Quarter 2024 Financial Results and Business Highlights
4:09pm
with advanced disease (e.g., Mayo Stage IV) are at the highest risk for early death. Birtamimab has been granted Fast Track designation by the FDA
8-K
EX-99.1
PRTA
Prothena Corporation plc
15 Feb 24
Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights
4:09pm
diagnosed individuals with advanced disease (e.g., Mayo Stage IV) are at the highest risk for early death. Birtamimab has been granted Fast Track designation
8-K
EX-99.1
3lz h6sxt7rq84omiu
8 Jan 24
Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs
8:35am
8-K
EX-99.1
uw94vc6lcl5306ys
2 Nov 23
Prothena Reports Third Quarter 2023 Financial Results and Business Highlights
4:09pm
8-K
EX-99.1
cjc5e
3 Aug 23
Prothena Reports Second Quarter 2023 Financial Results and Business Highlights
4:10pm
8-K
EX-99.1
ny4zz5j q1y
4 May 23
Prothena Reports First Quarter 2023 Financial Results and Business Highlights
4:08pm